A statement released earlier today by Zacks Investment Research about GlaxoSmithKline plc (ADR) (NYSE:GSK) bumps the target price to $48.00
- Updated: September 27, 2016
Just yesterday GlaxoSmithKline plc (ADR) (NYSE:GSK) traded 0.34% higher at $42.96. GlaxoSmithKline plc (ADR)’s 50-day moving average is $43.70 and its 200-day moving average is $42.70. The last closing price is up 0.95% from the 200-day moving average, compared to the Standard & Poor's 500 Index which has decreased -0.01% over the same time period. 937,730 shares of GSK traded hands, down from an average trading volume of 2,967,600
Zacks Investment Research bumped up the price target of GlaxoSmithKline plc (ADR) (NYSE:GSK) to $48.00 stating a potential upside of 0.12%.
Recent Performance Chart
GlaxoSmithKline plc (ADR) has 52 week low of $37.24 and a 52 week high of $45.58 with a P/E ratio of 2,694.06 and has a market cap of $0.
In addition to Zacks Investment Research reporting its target price, a total of 3 firms have reported on the stock. The consensus target price is $47.33 with 2 firms rating the stock a strong buy, 0 firms rating the stock a buy, 2 firms rating the stock a hold, 0 firms rating the stock a underperform, and finally 0 firms rating the stock a sell.
About GlaxoSmithKline plc (ADR) (NYSE:GSK)
GlaxoSmithKline plc (GSK) is a healthcare company. The Company is engaged in the creation and discovery, development, manufacture and marketing of pharmaceutical products, including vaccines, over-the-counter (OTC) medicines and health-related consumer products. The Company's segments include Pharmaceuticals, Pharmaceuticals R&D, Vaccines and Consumer Healthcare. The Pharmaceuticals business develops and makes medicines to treat a range of acute and chronic diseases. The Vaccines business develops, produces and distributes over 1.9 million vaccines every day to people across the world. The Consumer Healthcare business develops and markets products in various categories, such as Wellness, Oral health, Nutrition and Skin health. The Pharmaceuticals Research and Development (R&D) focuses on the discovery and development in various areas of research, which include human immunodeficiency virus (HIV) and infectious diseases, oncology, immuno-inflammation, respiratory and rare diseases.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.